These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1096 related articles for article (PubMed ID: 32081779)

  • 1. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
    Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
    Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chitooligosaccharides Modified Reduction-Sensitive Liposomes: Enhanced Cytoplasmic Drug Delivery and Osteosarcomas-Tumor Inhibition in Animal Models.
    Yin X; Chi Y; Guo C; Feng S; Liu J; Sun K; Wu Z
    Pharm Res; 2017 Oct; 34(10):2172-2184. PubMed ID: 28726003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palmitoyl ascorbate and doxorubicin co-encapsulated liposome for synergistic anticancer therapy.
    Yang Y; Lu X; Liu Q; Dai Y; Zhu X; Wen Y; Xu J; Lu Y; Zhao D; Chen X; Li N
    Eur J Pharm Sci; 2017 Jul; 105():219-229. PubMed ID: 28526602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal Doxorubicin: the Sphingomyelin/Cholesterol System Significantly Enhances the Antitumor Efficacy of Doxorubicin.
    Meng X; Zhang H; Chen L; Wang M; Zhang K; Liu X; Deng Y; Song Y
    AAPS PharmSciTech; 2023 Feb; 24(2):64. PubMed ID: 36759405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrasound-mediated cavitation enhances the delivery of an EGFR-targeting liposomal formulation designed for chemo-radionuclide therapy.
    Thomas E; Menon JU; Owen J; Skaripa-Koukelli I; Wallington S; Gray M; Mannaris C; Kersemans V; Allen D; Kinchesh P; Smart S; Carlisle R; Vallis KA
    Theranostics; 2019; 9(19):5595-5609. PubMed ID: 31534505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.
    Yu KF; Zhang WQ; Luo LM; Song P; Li D; Du R; Ren W; Huang D; Lu WL; Zhang X; Zhang Q
    Int J Nanomedicine; 2013; 8():2473-85. PubMed ID: 23885174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-permeable smart liposomes by modulating the tumor microenvironment to improve the chemotherapy.
    Widjaya AS; Liu Y; Yang Y; Yin W; Liang J; Jiang Y
    J Control Release; 2022 Apr; 344():62-79. PubMed ID: 35182612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent.
    Liu J; Chi D; Pan S; Zhao L; Wang X; Wang D; Wang Y
    Int J Pharm; 2019 Feb; 557():264-272. PubMed ID: 30599233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA; Abnous K; Badiee A; Jaafari MR
    Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma.
    Xiao K; Luo J; Li Y; Lee JS; Fung G; Lam KS
    J Control Release; 2011 Oct; 155(2):272-81. PubMed ID: 21787818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
    Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
    Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.
    Kibria G; Hatakeyama H; Sato Y; Harashima H
    Int J Pharm; 2016 Jul; 509(1-2):178-187. PubMed ID: 27234700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photosensitizer-Doped and Plasma Membrane-Responsive Liposomes for Nuclear Drug Delivery and Multidrug Resistance Reversal.
    Zhu YX; Jia HR; Duan QY; Liu X; Yang J; Liu Y; Wu FG
    ACS Appl Mater Interfaces; 2020 Aug; 12(33):36882-36894. PubMed ID: 32666795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug.
    Ling L; Ismail M; Du Y; Yao C; Li X
    Int J Pharm; 2019 Apr; 560():246-260. PubMed ID: 30769133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Physicochemical Property of iRGD Peptide Modified Doxorubicin Loaded Liposome and Its Effect on Cancer Cell Growth].
    Zhang ZQ; Zhong CL; Zhao X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Nov; 46(6):837-41. PubMed ID: 26867317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coencapsulation of alendronate and doxorubicin in pegylated liposomes: a novel formulation for chemoimmunotherapy of cancer.
    Shmeeda H; Amitay Y; Gorin J; Tzemach D; Mak L; Stern ST; Barenholz Y; Gabizon A
    J Drug Target; 2016 Nov; 24(9):878-889. PubMed ID: 27187807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
    Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
    J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
    Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
    Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cationic Polymethacrylate-Modified Liposomes Significantly Enhanced Doxorubicin Delivery and Antitumor Activity.
    Wang W; Shao A; Zhang N; Fang J; Ruan JJ; Ruan BH
    Sci Rep; 2017 Feb; 7():43036. PubMed ID: 28225062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy.
    Fernandes RS; Silva JO; Monteiro LOF; Leite EA; Cassali GD; Rubello D; Cardoso VN; Ferreira LAM; Oliveira MC; de Barros ALB
    Biomed Pharmacother; 2016 Dec; 84():252-257. PubMed ID: 27664949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.